Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

18.44 -0.15 (-0.81%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
24 25 Next >
Nasdaq, S&amp;P 500 Futures Slip Ahead Of Inflation Data — But Analyst Hints It Still Might Be Ok To Be Bullish
Via Benzinga
Disney, Occidental Petroleum And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Investor Sentiment Improves Slightly Ahead Of Key Inflation Reports
The CNN Money Fear and Greed index showed slight improvement in overall sentiment among U.S. investors on Tuesday. 
Via Benzinga
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
From Teva Pharmaceutical Industries Limited
Via Business Wire
FDA Approves Teva/MedinCell's Antipsychotic Injection For Adult Schizophrenia Patients
Via Benzinga
Busy Week Ahead As Volatility Gauges Flash Red
With CPI data being released on Wednesday and the Biden administration starting talks with Congress on Tuesday, it looks like this could be a big week for volatility. 
Via Talk Markets
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Launch New Growth Strategy at Investor Day
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
Merck is branching into immune-mediated diseases with this takeover. 
Via Investor's Business Daily
1 "Safe" Stock to Avoid and 1 to Consider Buying in April
There's more to the concept of safety than having a business model that looks safe. 
Via The Motley Fool
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday. 
Via Benzinga
Boeing, Spirit AeroSystems And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Complete Response Letter Received for AVT02 Biologics License Application
From Teva Pharmaceutical Industries Limited
Via Business Wire
Trillions In Biotech Stock Gains Trace Back To This Financier
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider. 
Via Investor's Business Daily
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
7 A-Rated Stocks to Buy for April 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape. 
Via InvestorPlace
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
Millions of people are scrambling to get their ADHD medication. Here's why. 
Via Investor's Business Daily
Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva
Via Benzinga
Is Big Pharma Coming For Your Cannabis Business?
Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies... 
Via Benzinga
Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
From Teva Pharmaceutical Industries Limited
Via Business Wire
7 Strong Buy Stocks Under $10 to Snap Up Now
Markets are missing out on these seven strong buy stocks under $10, which trade at too good a value score for savvy investors to ignore. 
Via InvestorPlace
3 No-Brainer Stocks to Buy With $10 Right Now
You don't need a large pile of money to begin building wealth on Wall Street. 
Via The Motley Fool
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
The guidance includes Catalyst's newest, and second, product. 
Via Investor's Business Daily
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
From Teva Pharmaceutical Industries Limited
Via Business Wire
7 Core Stocks to Build a Solid Portfolio Around
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.